Hikma introducing generic Xenazine
Hikma is offering tetrabenazine tablets, in dosage strengths of 12.5 mg and 25 mg.
The product is the generic equivalent of Lundbeck's Xenazine.
Tetrabenazine tablets are a vesicular monoamine transporter inhibitor indicated for the treatment of chorea associated with Huntington’s disease.
Tetrabenazine tablets, 12.5 mg and 25 mg, had a market value of roughly $119 million in the 12 months ended July 2019, according to IQVIA.
The product is the generic equivalent of Lundbeck's Xenazine.
Tetrabenazine tablets are a vesicular monoamine transporter inhibitor indicated for the treatment of chorea associated with Huntington’s disease.
Tetrabenazine tablets, 12.5 mg and 25 mg, had a market value of roughly $119 million in the 12 months ended July 2019, according to IQVIA.